ScoreWhy is RPG Life Sciences Ltd ?
1
The company is Net-Debt Free
2
Poor long term growth as Net Sales has grown by an annual rate of 12.70% and Operating profit at 18.64% over the last 5 years
3
Flat results in Mar 26
- ROCE(HY) Lowest at 24.18%
- PBT LESS OI(Q) At Rs 26.74 cr has Fallen at -9.3% (vs previous 4Q average)
4
With ROE of 18.6, it has a Fair valuation with a 6.5 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 18.04%, its profits have risen by 18% ; the PEG ratio of the company is 1.9
5
Despite the size of the company, domestic mutual funds hold only 0.15% of the company
- Domestic mutual funds have capability to do in-depth on-the-ground research on companies- their small stake may signify either they are not comfortable at the price or the business
6
Consistent Returns over the last 3 years
- Along with generating 18.04% returns in the last 1 year, the stock has outperformed BSE500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to RPG LifeScience. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is RPG LifeScience. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
RPG LifeScience.
18.04%
0.51
35.69%
Sensex
-3.33%
-0.25
13.43%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
12.70%
EBIT Growth (5y)
18.64%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.36
Sales to Capital Employed (avg)
1.53
Tax Ratio
25.31%
Dividend Payout Ratio
21.66%
Pledged Shares
0
Institutional Holding
8.32%
ROCE (avg)
41.11%
ROE (avg)
20.40%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
36
Industry P/E
34
Price to Book Value
6.48
EV to EBIT
29.48
EV to EBITDA
25.18
EV to Capital Employed
9.63
EV to Sales
5.24
PEG Ratio
1.94
Dividend Yield
1.01%
ROCE (Latest)
32.66%
ROE (Latest)
18.57%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend5What is working for the Company
PAT(Q)
Highest at Rs 29.08 cr.
CASH AND CASH EQUIVALENTS(HY)
Highest at Rs 156.78 cr
-4What is not working for the Company
ROCE(HY)
Lowest at 24.18%
PBT LESS OI(Q)
At Rs 26.74 cr has Fallen at -9.3% (vs previous 4Q average
Loading Valuation Snapshot...
Here's what is working for RPG LifeScience.
Profit After Tax (PAT) - Quarterly
Highest at Rs 29.08 cr. and Grown
each quarter in the last five quartersMOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Cash and Cash Equivalents - Half Yearly
Highest at Rs 156.78 cr
in the last six half yearly periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Here's what is not working for RPG LifeScience.
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 26.74 cr has Fallen at -9.3% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 29.49 CrMOJO Watch
Near term PBT trend is negative
PBT less Other Income (Rs Cr)
Non Operating Income - Quarterly
Highest at Rs 12.36 cr
in the last five quartersMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating Income
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
